Review of advanced research on swinevaccine development strategy.

Abstract

(App) infection is a major respiratory disease that causes severe economic losses. It is highly infectious and exhibits multiple serotypes, which complicates prevention and control. This review discusses the new-generation vaccine development strategies and the role of virulence factors-such as App toxins, capsular polysaccharide (CPS), lipopolysaccharide (LPS), and outer membrane proteins (OMPs)-in vaccine design. Traditional vaccines offer limited cross-protection, whereas live attenuated vaccines, subunit vaccines, and toxin-based vaccines show promising improvements in efficacy and safety. Current and near-generation subunit and toxin vaccines mainly focus on conserved antigens, incorporating App toxins, OMPs ApfA, and GALT, which significantly enhance cross-protection and safety. Other approaches, including DNA vaccines and combined multivalent vaccines targeting highly prevalent App serotypes and integrating antigens from other pathogens, represent a modern strategy aimed at enhancing cross-serotype protection, minimizing side effects, and enabling differentiating infected from vaccinated animal (DIVA) capability.